File No: STD/1308

February 2009

# NATIONAL INDUSTRIAL CHEMICALS NOTIFICATION AND ASSESSMENT SCHEME (NICNAS)

# **FULL PUBLIC REPORT**

# **Z-89**

This Assessment has been compiled in accordance with the provisions of the *Industrial Chemicals (Notification and Assessment) Act 1989* (Cwlth) (the Act) and Regulations. This legislation is an Act of the Commonwealth of Australia. The National Industrial Chemicals Notification and Assessment Scheme (NICNAS) is administered by the Department of Health and Ageing, and conducts the risk assessment for public health and occupational health and safety. The assessment of environmental risk is conducted by the Department of the Environment, Water, Heritage and the Arts.

For the purposes of subsection 78(1) of the Act, this Full Public Report may be inspected at our NICNAS office by appointment only at 334-336 Illawarra Road, Marrickville NSW 2204.

This Full Public Report is also available for viewing and downloading from the NICNAS website or available on request, free of charge, by contacting NICNAS. For requests and enquiries please contact the NICNAS Administration Coordinator at:

Street Address: 334 - 336 Illawarra Road MARRICKVILLE NSW 2204, AUSTRALIA.

Postal Address: GPO Box 58, SYDNEY NSW 2001, AUSTRALIA.

TEL: + 61 2 8577 8800 FAX + 61 2 8577 8888 Website: www.nicnas.gov.au

Director NICNAS

# TABLE OF CONTENTS

FULL P	UBLIC REPORT	
1.	APPLICANT AND NOTIFICATION DETAILS	3
2.	IDENTITY OF CHEMICAL	
3.	COMPOSITION	3
4.	PHYSICAL AND CHEMICAL PROPERTIES	4
5.	INTRODUCTION AND USE INFORMATION	4
6.	HUMAN HEALTH IMPLICATIONS	5
7.	ENVIRONMENTAL IMPLICATIONS	
8.	CONCLUSIONS AND REGULATORY OBLIGATIONS	9
APPENI	DIX A: PHYSICAL AND CHEMICAL PROPERTIES	11
	DIX B: TOXICOLOGICAL INVESTIGATIONS	
	DIX C: ENVIRONMENTAL FATE AND ECOTOXICOLOGICAL INVESTIGATIONS	
	GR APHV	23

# **FULL PUBLIC REPORT**

# **Z-89**

#### 1. APPLICANT AND NOTIFICATION DETAILS

APPLICANT(S)
Lubrizol International Inc (ABN 52 073 495 603)
28 River Street
Silverwater NSW 2128

NOTIFICATION CATEGORY

Standard: Chemical other than polymer (more than 1 tonne per year).

EXEMPT INFORMATION (SECTION 75 OF THE ACT)

Data items and details claimed exempt from publication: Chemical name, CAS number, molecular formula, structural formula, molecular weight, means of identification, purity, identity of impurities, details of use and import volume.

VARIATION OF DATA REQUIREMENTS (SECTION 24 OF THE ACT)

Variation to the schedule of data requirements is claimed as follows: Dissociation constant, bioaccumulation, flammability limits, acute inhalation toxicity and induction of germ cell damage.

PREVIOUS NOTIFICATION IN AUSTRALIA BY APPLICANT(S) None

NOTIFICATION IN OTHER COUNTRIES

The notified chemical is currently being notified globally.

# 2. IDENTITY OF CHEMICAL

MARKETING NAME(S) Z-89

OTHER NAME(S)
OS219479 (Used for testing and trials)

MOLECULAR WEIGHT < 500 Da

ANALYTICAL DATA

Reference NMR, IR and UV spectra were provided.

# 3. COMPOSITION

DEGREE OF PURITY > 92%

ADDITIVES/ADJUVANTS None

#### 4. PHYSICAL AND CHEMICAL PROPERTIES

APPEARANCE AT 20°C AND 101.3 kPa: Pale yellow, slightly viscous liquid

Property	Value	Data Source/Justification	
Pour point	-20°C	Measured	
Boiling Point	Boiled with decomposition at	Measured	
	371°C at 101.3 kPa		
Density	959 kg/m <sup>3</sup> at 20°C	Measured	
Vapour Pressure	$2.0 \times 10^{-8}$ kPa at 25°C	Measured	
Water Solubility	$\leq 1.21 \times 10^{-4} \text{ g/L at } 20^{\circ}\text{C}$	Measured	
Hydrolysis as a Function of pH	Stable at pH 4 and 7 (half-life more	Measured	
	than a year). Hydrolysed at pH 9		
	(half-life 15.2 days).		
Partition Coefficient	$\log Pow = 7.18$ at $20^{\circ}C$	Measured	
(n-octanol/water)			
Adsorption/Desorption	$\log K_{\rm oc} > 5.63$	Measured	
Dissociation Constant	pKa = 12.3	Estimated	
Flash Point	129°C at 101 kPa (closed cup)	Measured	
Flammability	Not expected to be highly	Estimated from measured flash point.	
	flammable		
Autoignition Temperature	356°C	Measured	
Explosive Properties	Not explosive	Estimated based on chemical structure	
Oxidising Properties	Not oxidising	Estimated based on chemical structure	

#### DISCUSSION OF PROPERTIES

For full details of tests on physical and chemical properties, please refer to Appendix A.

The notified chemical has a low vapour pressure, is highly lipophilic and sparingly soluble in water.

Based on the flash point, the notified chemical is not classified as flammable but would be considered to be a C1 combustible liquid [NOHSC:1015(2001)]

#### Reactivity

Stable under normal conditions of use.

# 5. INTRODUCTION AND USE INFORMATION

Mode of Introduction of Notified Chemical (100%) Over Next 5 Years

The notified chemical will not be manufactured in Australia. The notified chemical will be imported as a component of finished lubricant at a concentration of  $\leq 2\%$ . The notified chemical may also be imported in a more concentrated product ( $\leq 10\%$ ) for reformulation within Australia.

MAXIMUM INTRODUCTION VOLUME OF NOTIFIED CHEMICAL (100%) OVER NEXT 5 YEARS

Year	1	2	3	4	5
Tonnes	100-200	300-400	300-400	300-400	400-500

# PORT OF ENTRY

Throughout Australia.

#### TRANSPORTATION AND PACKAGING

The products containing the notified chemical will be imported in isotainers and 55 and 330 gallon drums and will be transported throughout Australia by road or rail.

#### USE

The notified chemical will be used as an engine oil additive (concentration  $\leq 2\%$ ).

#### OPERATION DESCRIPTION

The notified chemical will not be manufactured in Australia, but may be reformulated after importation.

#### Reformulation

At customer blending sites, the concentrate product containing the notified chemical (at  $\leq$  10%) will be formulated into engine oil products by mixing with oil and other additives. It will be either decanted from drums or isotainers into a trough from which it will be pumped into a blend tank, or pumped directly into the blend tank. Blend facilities are expected to be fully automated, well ventilated and closed systems.

After blending, the engine oil products containing the notified chemical (at  $\leq$  2%) will be packaged into containers. The packaging facility will usually be located near the blending operation area and the transfer of product to the packaging is expected to be fully automated.

Samples may be taken during the blending process for quality control testing. The samples will be collected by opening a valve in the blending vessel and filling a small container.

#### End use

Engine oil products containing  $\leq 2\%$  of the notified chemical will primarily be used in factories where cars are manufactured. The engine oil products containing  $\leq 2\%$  of the notified chemical may also be used in mechanical repair garages and sold to the public.

#### 6. HUMAN HEALTH IMPLICATIONS

#### **6.1** Exposure assessment

#### 6.1.1 Occupational exposure

#### **EXPOSURE DETAILS**

Storage and transportation

It is anticipated that waterside workers, transport drivers and warehouse workers would only be exposed to the material in the event of an accident

#### Reformulation

Dermal and ocular exposure to the notified chemical ( $\leq$  10%) is possible when plant operators are connecting and disconnecting pump lines to storage tanks or blending vessels. It is expected that negligible exposure will occur during the fully automatic and closed blending process. The opportunity also exists for dermal exposure ( $\leq$  2%) when cleaning up spills or leaks and during maintenance of the blend vessel. However, maintenance is not expected to occur frequently as residue in the blending vessel will generally be incorporated into the next blend. Workers involved in the blending process are expected to wear impermeable gloves, goggles or face shield and protective clothing to further minimise exposure.

Negligible exposure is expected during transfer of the concentrate product containing the notified chemical ( $\leq 2\%$ ) to packaging as this will be carried out using automated processes. Inhalation exposure is expected to be negligible given the very low vapour pressure of the notified chemical ( $2.0 \times 10^{-8}$  kPa at  $25^{\circ}$ C). In addition, blending and packaging facilities are expected to be well ventilated.

#### Sampling

At blending facilities samples will be taken from blend vessels during the blending process. Dermal exposure to the notified chemical (at  $\leq$  2%) may occur during sampling. To minimise exposure the plant operator is expected to wear gloves, goggles and protective clothing.

#### End use

There is potential for dermal exposure during the connection and disconnection of the dip-pipe and pump as well as from handling automotive components contaminated with the engine oil. At workshops, mechanics may experience dermal and ocular exposure to final products containing < 2% of the notified chemical when adding the products to automobiles and other machinery. Exposure is expected to be minimised by the use of gloves, goggles and protective clothing.

#### 6.1.2. Public exposure

Products containing the notified polymer are primarily intended for use by industry and therefore public exposure to the notified polymer is expected to be low. However, exposure to the notified polymer ( $\leq 2\%$ ) may occur during the changing of engine oil in automobiles by the public, although this will only be on an infrequent basis. Exposure will primarily be dermal, although ocular exposure is also possible. PPE is not expected to be worn by the public.

#### 6.2. Human health effects assessment

The results from toxicological investigations conducted on the notified chemical are summarised in the table below. Details of these studies can be found in Appendix B.

Endpoint	Result and Assessment Conclusion
Rat, acute oral toxicity	oral LD50 > 2000 mg/kg bw
	low toxicity
Rat, acute dermal toxicity	LD50 > 2000  mg/kg bw
	low toxicity
Rat, acute inhalation toxicity	Not determined
Rabbit, skin irritation	slightly irritating
Rabbit, eye irritation	slightly irritating
Mouse, skin sensitisation – Local lymph node assay	no evidence of sensitisation
Rat, repeat dose oral toxicity – 28 days.	NOAEL = 750  mg/kg bw/day
Mutagenicity – bacterial reverse mutation	non mutagenic
Genotoxicity - in vitro Mammalian Chromosome	non genotoxic
Aberration Test	
Genotoxicity – in vivo	Not determined

#### Toxicokinetics, metabolism and distribution.

Based on the low molecular weight (< 500 Da) and the lipophilicity of the notified chemical (water solubility  $\leq 1.21 \times 10^{-4}$  g/L at 20°C; log Pow = 7.18 at 20°C) dermal absorption may occur, but the transfer from the stratum corneum into the epidermis is expected to be slow.

#### Acute toxicity

The notified chemical is considered to be of low acute toxicity via the oral and dermal routes based on tests conducted in rats.

# Irritation and Sensitisation.

Based on a test conducted in rabbits the notified chemical is considered to be slightly irritating to the skin and eye. The notified chemical was found to be a non-sensitiser in a local lymph node assay in mice.

# Repeated Dose Toxicity (sub acute, sub chronic, chronic).

Oral administration of the test material to rats for a period of 28 consecutive days at dose levels of 750, 150 and 25 mg/kg/day resulted in treatment related effects at all dose levels and therefore a No Observed Effect Level (NOEL) could not be set. The treatment related effects were limited to microscopic liver and thyroid changes, with associated liver weight gains and a slightly altered metabolism. There were no associated inflammatory or degenerative changes in the organs affected, and so the effects are considered to be an adaptive response to the high doses of xenobiotics.

Therefore, the No Observed (Adverse) Effect Level (NO(A)EL) was established as 750 mg/kg bw/day in this study, based on the lack of toxicologically relevant effects seen in the study.

# Mutagenicity and carcinogenicity.

The notified chemical was found to not be mutagenic using a bacterial reverse mutation test, and is not clastogenic to Chinese hamster lung cells *in vitro*.

#### Health hazard classification

Based on the available data the notified chemical is not classified as hazardous under the *Approved Criteria for Classifying Hazardous Substances* (NOHSC, 2004).

#### 6.3. Human health risk characterisation

#### 6.3.1. Occupational health and safety

Occupational dermal and ocular exposure to the notified chemical for reformulation workers may occur during handling of the drums or isotainers, transfer of the concentrate product ( $\leq 10\%$ ) into the blend tank, cleaning and maintenance of the equipment. Dermal and ocular exposure may also occur in the end use where engine oil ( $\leq 2\%$  notified chemical) is changed by automotive mechanics.

#### Local effects

Although the notified chemical is a slight eye and skin irritant, the severity of these effects will be reduced due to the relatively low concentrations in the products. In addition the exposure is expected to be minimised due to the use of personal protective equipment in the case of reformulation workers. Therefore the risk of irritation is not expected.

#### Systemic effects

The NOAEL for the notified chemical was found to be 750 mg/kg bw/day. The chemical is not acutely toxic via the oral or dermal routes and was not mutagenic or genotoxic.

Dermal exposure to the notified chemical during reformulation activities can be estimated using the EASE (1997) model assuming reasonable worst case defaults and based on non-dispersive use with intermittent direct handling. This gives an estimated daily exposure of 0.12 mg/kg bw/day for a 70 kg worker, assuming a 10% dermal absorption factor and an average surface area of 860 cm² for the hands (RVIM, 2006). Based on a 750 mg/kg bw/day NOAEL for the notified chemical derived from a 28-day rat oral repeat dose study the margin of exposure (MOE) for the proposed use is 6250. A MOE greater than or equal to 100 is considered acceptable to account for intra- and inter-species differences. Therefore, the risk of systemic effects is acceptable for workers involved in reformulation of products containing the notified chemical. For end-users the risk of repeated exposure to the notified chemical is reduced due to the lower concentrations  $\leq 2\%$ ).

The risk of repeated exposure is not considered unacceptable, considering the estimated MOE and the toxicological profile of the notified chemical.

# 6.3.2. Public health

The risk to the public is low assuming that most consumers do not change their own engine oil. For DIY users changing their own engine oil the risk is not considered unacceptable, given that draining of engine oil is an infrequent event and the concentration of the notified chemical in the engine oil is low.

#### 7. ENVIRONMENTAL IMPLICATIONS

# 7.1. Environmental Exposure & Fate Assessment

#### 7.1.1 Environmental Exposure

#### RELEASE OF CHEMICAL AT SITE

The notification dossier states that the notified chemical will initially be imported as part of a finished engine oil. Should local blending commence, releases would be expected to be low as blending facilities use highly automated processes. Spills would be recycled or collected for incineration, together with residues rinsed from import containers, estimated at 1% of the import volume.

#### RELEASE OF CHEMICAL FROM USE

Some minor, diffuse exposure will result from spills during addition to and removal of oil from vehicles. Around 86% of oil changes take place in specialised automotive service centres, where release of the notified chemical from professional activities should be disposed of appropriately. The remaining 14% are removed by DIY enthusiasts. The DIY proportion of oil changes could potentially lead to improper disposal of used oil (55%) to soils or sediments and stormwater drains.

# RELEASE OF CHEMICAL FROM DISPOSAL

Iso-containers and drums should be sent for cleaning and reconditioning by a licensed company. The resultant washings from such companies are typically passed to an on site waste treatment facility, with any waste sludge typically incinerated.

Old oil drained from crankcases at specialised automotive service centres is expected to be disposed of responsibly, either to oil recycling facilities or incineration.

Oils disposed of by DIY enthusiasts would be either incinerated, left at transfer stations where it is again likely to be recycled, or deposited into landfill. However, a survey tracing the fate of used lubricating oil in Australia found that only around 20% of used oil removed by enthusiasts is collected for recycling, approximately 25% is buried or disposed of in landfill, 5% is disposed of into stormwater drains and the remaining 50% is used in treating fence posts, killing grass and weeds or disposed of in other ways.

#### 7.1.2 Environmental fate

The notified chemical is likely to mainly be disposed of by incineration. Smaller amounts may be consigned to landfill, or disposed of inappropriately to land or stormwater. Incineration would destroy the notified chemical, while disposal to land or landfill would result in its immobilisation because of the strong sorption to soil organic carbon. If disposed of to water, the notified chemical is likely to spread across the surface of the water and sorb to suspended solids and sediment. The notified chemical is not readily biodegradable, but can be expected to slowly degrade in the environment. Bioaccumulation is not expected to be a significant pathway because the notified chemical has a very low water solubility and high octanol-water partition coefficient (> 10<sup>7</sup>) and is therefore not expected to be bioavailable to aquatic organisms.

For the details of the environmental fate studies please refer to Appendix C.

# 7.1.3 Predicted Environmental Concentration (PEC)

A worst case estimated PEC might be calculated if it is assumed that 0.7% of the notified chemical (maximum 3.5 tonne) is released into stormwater drains in a single metropolitan area with a geographical footprint of  $500 \text{ km}^2$  and an average annual rainfall of 500 mm, all of which drains to stormwater. With a maximum annual release into this localised stormwater system of 3500 kg and the annual volume of water drained from this region estimated to be approximately  $250 \times 10^6 \text{ m}^3$ , the resultant PEC is approximately 14 µg/L. It should be stressed that this result is very much a worst case scenario, and that in reality releases of the notified chemical would be very much more diffuse than indicated here, and also at significantly reduced levels.

#### 7.2. Environmental effects assessment

The results from ecotoxicological investigations conducted on the notified chemical are summarised in the table below. Details of these studies can be found in Appendix C.

Endpoint	Result	Assessment Conclusion
Fish Toxicity	EC50 > 0.0011  mg/L	
Daphnia Toxicity	EC50 > 0.0082  mg/L	Nontoxic to the limit of water solubility,
Algal Toxicity	EC50 > 0.00018  mg/L	as modulated by the instability of the
Inhibition of Bacterial Respiration	EC50 > 1000  mg/L	notified chemical.

The fish, daphnid and algal tests were conducted with water accommodated fractions obtained by mid-depth siphon from stirred suspensions. Results are expressed as mean measured concentrations. Their variability reflects the hydrophobicity of the notified chemical and its instability under the test conditions as seen in preliminary stability analyses. The result for the bacterial inhibition test is expressed as the nominal concentration.

# 7.2.1 Predicted No-Effect Concentration

Where acute toxicity data are available for three trophic levels, the predicted no effect concentration is normally derived by application of an assessment factor of 100 to the median effect concentration in the most sensitive species. This approach is impractical for the notified chemical as the median effect concentrations are not known. The notified chemical had no harmful acute effects in fish, daphnids or algae at concentrations up to the solubility limit, as modulated by its degradation. The mean measured no effect concentrations varied from  $0.18~\mu g/L$  to  $8.2~\mu g/L$ .

#### 7.3. Environmental risk assessment

Comparison of the PEC of  $14~\mu g/L$  with the mean measured no-effect concentrations of  $0.18-8.2~\mu g/L$  suggests the possibility of toxic effects in aquatic life exposed to residues of the notified chemical that have been inappropriately disposed of to stormwater. However, in practical terms the notified chemical is not expected to pose a risk to the environment. This is because the PEC overestimates the likely level of exposure, as it reflects a worst case scenario with no consideration of the strong hydrophobicity of the notified chemical, which would favour sorption to sediment rather than dissolution in the water column. The actual no-effect concentrations are likely to be higher than the values obtained from testing, which are limited by the very low water solubility and instability of the notified chemical. Accidental spills of the notified chemical to water can be expected to be harmful to aquatic life, as it would be likely to coat biological membranes in such situations, but the notified chemical is not expected to pose a risk to the environment when it is used as proposed in engine oils.

#### 8. CONCLUSIONS AND REGULATORY OBLIGATIONS

#### Hazard classification

Based on the available data the notified chemical is not classified as hazardous under the *Approved Criteria for Classifying Hazardous Substances* [NOHSC:1008(2004)].

#### Human health risk assessment

Under the conditions of the occupational settings described, the notified chemical is not considered to pose an unacceptable risk to the health of workers.

When used in the proposed manner, the notified chemical is not considered to pose an unacceptable risk to public health.

#### **Environmental risk assessment**

On the basis of the very low water solubility and the reported use pattern, the notified chemical is not considered to pose a risk to the environment.

# Recommendations

CONTROL MEASURES
Occupational Health and Safety

- Employers should implement the following safe work practices to minimise occupational exposure during handling of products containing the notified chemical:
  - Avoid skin and eye contact
- Employers should ensure that the following personal protective equipment is used by workers to minimise occupational exposure to products containing the notified chemical:
  - Protective eyewear
  - Impervious gloves
  - Protective clothing

Guidance in selection of personal protective equipment can be obtained from Australian, Australian/New Zealand or other approved standards.

- A copy of the MSDS should be easily accessible to employees.
- If products and mixtures containing the notified chemical are classified as hazardous to health in accordance with the *Approved Criteria for Classifying Hazardous Substances* [NOHSC:1008(2004)] workplace practices and control procedures consistent with provisions of State and Territory hazardous substances legislation must be in operation.

# Disposal

• The notified chemical should be disposed of by landfill.

# **Regulatory Obligations**

#### Secondary Notification

This risk assessment is based on the information available at the time of notification. The Director may call for the reassessment of the chemical under secondary notification provisions based on changes in certain circumstances. Under Section 64 of the *Industrial Chemicals (Notification and Assessment) Act (1989)* the notifier, as well as any other importer or manufacturer of the notified chemical, have post-assessment regulatory obligations to notify NICNAS when any of these circumstances change. These obligations apply even when the notified chemical is listed on the Australian Inventory of Chemical Substances (AICS).

Therefore, the Director of NICNAS must be notified in writing within 28 days by the notifier, other importer or manufacturer:

# (1) Under Section 64(2) of the Act; if

- the function or use of the chemical has changed from an engine oil additive, or is likely to change significantly;
- the amount of chemical being introduced has increased from 500 tonnes, or is likely to increase, significantly;
- the chemical has begun to be manufactured in Australia;
- additional information has become available to the person as to an adverse effect of the chemical on occupational health and safety, public health, or the environment.

The Director will then decide whether a reassessment (i.e. a secondary notification and assessment) is required.

No additional secondary notification conditions are stipulated.

#### Material Safety Data Sheet

The MSDS of the products containing the notified chemical provided by the notifier were reviewed by NICNAS. The accuracy of the information on the MSDS remains the responsibility of the applicant.

# **APPENDIX A: PHYSICAL AND CHEMICAL PROPERTIES**

**Melting Point/Freezing Point** -20°C

Method OECD TG 102 Melting Point/Melting Range.

Remarks No significant protocol deviations. Test Facility Safepharm Laboratories (2007a)

**Boiling Point** 371°C at 101.3 kPa

Method OECD TG 103 Boiling Point.

Remarks The boiling point was determined using differential scanning calorimetry.

Decomposition was noted along with boiling. The decomposition occurred under both air

and nitrogen atmospheres indicating that decomposition was not oxidative.

No significant protocol deviations.

Test Facility Safepharm Laboratories (2007a)

**Density** 959 kg/m<sup>3</sup> at 20°C

Method OECD TG 109 Density of Liquids and Solids.

Remarks The relative density was determined using the pycnometer method.

No significant protocol deviations.

Test Facility Safepharm Laboratories (2007a)

**Vapour Pressure**  $2.0 \times 10^{-8}$  kPa at 25°C

Method OECD TG 104 Vapour Pressure.

Remarks The vapour pressure was determined using a vapour pressure balance at several

temperatures, with linear regression analysis used to determine the vapour pressure at

25°C. No significant protocol deviations.

Test Facility Safepharm Laboratories (2007b)

Water Solubility  $\leq 1.21 \times 10^{-4} \text{ g/L at } 20^{\circ}\text{C}$ 

Method OECD TG 105 Water Solubility.

Remarks Flask Method. The notified chemical was determined by HPLC analysis of

dichloromethane extracts of the saturated aqueous solutions obtained by centrifugation and filtration of dispersions prepared at a nominal 0.2 g/L. The value cited has been corrected for the low recovery (25%) from filtered solutions prepared at a nominal

0.25 mg/L.

The water solubility has also been estimated (EPIWIN version 3.12) as  $8.5 \times 10^{-7}$  g/L.

Test Facility SafePharm Laboratories (2007a)

# Hydrolysis as a Function of pH

Method OECD TG 111 Hydrolysis as a Function of pH.

EC Directive 92/69/EEC C.7 Degradation: Abiotic Degradation: Hydrolysis as a Function

of pH.

pН	$T(\mathcal{C})$	$t_{\frac{1}{2}}$
4	25	> 1 year
7	25	> 1 year
9	25	> 1 year > 1 year 15.2 days

Remarks The half-life at pH 9 was extrapolated from measurements at 30°C, 40°C and 50°C. The

nominal concentration was  $5 \times 10^{-5}$  g/L, below the solubility limit. Acetonitrile (1%) was used to assist in dissolution. Hydrolysis was expected to occur at pH 9, based on the

structure, and was confirmed by identification of the expected hydrolysis products.

Test Facility SafePharm Laboratories (2007a)

**Partition Coefficient (n-**  $log P_{ow} = 7.18 at 20^{\circ}C$ 

octanol/water)

Method OECD TG 117 Partition Coefficient (n-octanol/water).

Remarks HPLC Method. The test was conducted at neutral pH. The mobile phase was modified to

allow higher calibration reference standards (nonylbenzene and tridecylbenzene) to elute. The result from HPLC is consistent with the preliminary estimate (log  $P_{ow} > 5.19$ ) obtained from the approximate solubilities in octanol (415 g/L) and water (< 2.7 mg/L).

Test Facility SafePharm Laboratories (2007a)

**Adsorption/Desorption**  $\log K_{oc} > 5.63$ 

- screening test

Method OECD TG 121 Adsorption - Desorption HPLC Screening Method.

Remarks The notified chemical eluted from the HPLC column after the reference substance DDT.

Test Facility SafePharm Laboratories (2007a)

**Dissociation Constant** pKa = 12.3

Method Computer based estimation software.

Remarks Measurement could not be carried out because of the very low water solubility of the

notified chemical.

Test Facility SafePharm Laboratories (2007a)

Flash Point 129°C at 101 kPa

Method EC Directive 92/69/EEC A.9 Flash Point.

Remarks The flash point was determined using a closed cup equilibrium method. No significant

protocol deviations.

Test Facility Safepharm Laboratories (2007b)

**Autoignition Temperature** 356°C

Method EC Directive 92/69/EEC A.15 Auto-Ignition Temperature (Liquids and Gases).

Remarks No significant protocol deviations. Test Facility Safepharm Laboratories (2007b)

**Explosive Properties** Not explosive

Method EC Directive 92/69/EEC A.14 Explosive Properties.

Remarks The structure of the notified chemical was assessed for chemical groups that imply

explosive properties. No significant protocol deviations.

Test Facility Safepharm Laboratories (2007b)

Oxidizing Properties Not oxidising

Method EC Directive 92/69/EEC A.21 Oxidizing Properties (Liquids).

Remarks The structure of the notified chemical was assessed for chemical groups that imply

oxidising properties.

No significant protocol deviations.

Test Facility Safepharm Laboratories (2007b)

# APPENDIX B: TOXICOLOGICAL INVESTIGATIONS

#### **B.1.** Acute toxicity – oral

TEST SUBSTANCE Notified chemical

METHOD OECD TG 420 Acute Oral Toxicity - Fixed Dose Method.

EC Directive2004/73/EC B.1 bis Acute Toxicity (Oral) Fixed Dose

Method.

Species/Strain Rat/Sprague-Dawley CD (Crl : CD (SD) IGS BR) Female

Vehicle Test substance administered as supplied
Remarks - Method No significant protocol deviations.
All animals were dosed by gavage.

The sighting study was conducted using 1 animal dosed at 2000 mg/kg. As there was no mortality an additional four animals were dosed at

2000 mg/kg.

RESULTS

Discriminating Dose > 2000 mg/kg bw Signs of Toxicity There were no deaths.

No signs of systemic toxicity were noted.

Effects in Organs
Remarks - Results
No abnormalities were noted at necroscopy
Body weight gains were as expected.

CONCLUSION The notified chemical is of low toxicity via the oral route.

TEST FACILITY Safepharm Laboratories (2007c)

# **B.2.** Acute toxicity – dermal

TEST SUBSTANCE Notified chemical

METHOD OECD TG 402 Acute Dermal Toxicity – Limit Test.

EC Directive 92/69/EEC B.3 Acute Toxicity (Dermal) – Limit Test.

Species/Strain Rat/Sprague-Dawley CD (Crl: CD (SD) IGS BR)

Vehicle Test substance administered as supplied

Type of dressing Semi-occlusive.

Remarks - Method No significant protocol deviations

# RESULTS

Group	Number and Sex	Dose	Mortality
	of Animals	mg/kg bw	
I	5 per sex	2000	0

LD50 > 2000 mg/kg bw

Signs of Toxicity - Local There were no test substance-related dermal reactions.

Signs of Toxicity - Systemic There were no deaths or test-substance related clinical signs. There were

no signs of systemic toxicity.

Effects in Organs No abnormalities were noted at necroscopy Remarks - Results Body weight gains were as expected.

CONCLUSION The notified chemical is of low toxicity via the dermal route.

TEST FACILITY Safepharm Laboratories (2007d)

#### **B.3.** Irritation – skin

TEST SUBSTANCE Notified chemical

METHOD OECD TG 404 Acute Dermal Irritation/Corrosion.

EC Directive 2004/73/EC B.4 Acute Toxicity (Skin Irritation).

Species/Strain Rabbit/New Zealand White

Number of Animals 3 males

Vehicle Test substance administered as supplied

Observation Period 7 days

Type of Dressing Semi-occlusive.

Remarks - Method No significant protocol deviations

#### RESULTS

Lesion		an Sco nimal N	. •	Maximum Value	Maximum Duration of Any Effect	Maximum Value at End of Observation Period
	1	2	3			•
Erythema/Eschar	1	1	1.3	2	< 7 days	0
Oedema	0.3	0	0.7	1	< 72 hours	0

<sup>\*</sup>Calculated on the basis of the scores at 24, 48, and 72 hours for EACH animal.

Remarks - Results

A single 4-hour, semi-occluded application of the test material to the intact skin of the three rabbits produced very slight to well-defined erythema and very slight oedema at the 24 hour observation. Slight erythema was noted at all treated skin sites at 48 hours. One treated skin site appeared normal at the 72-hour observation and the remaining two treated skin sites appeared normal at the 7-day observation.

No corrosive effects were noted.

CONCLUSION The notified chemical is slightly irritating to the skin.

TEST FACILITY Safepharm Laboratories (2007e)

#### **B.4.** Irritation – eye

TEST SUBSTANCE Notified chemical

METHOD OECD TG 405 Acute Eye Irritation/Corrosion.

EC Directive 2004/73/EC B.5 Acute Toxicity (Eye Irritation).

Species/Strain Rabbit/New Zealand White

Number of Animals 3 males Observation Period 72 hours

Remarks - Method No significant protocol deviations

RESULTS

Lesion	Mean Score* Animal No.		Maximum Value	Maximum Duration of Any Effect	Maximum Value at End of Observation Period	
	1	2	3			
Conjunctiva: redness	0.7	0.7	1	2	< 72 hours	0
Conjunctiva: chemosis	0.3	0.3	0.3	1	< 48 hours	0
Conjunctiva: discharge	0.3	0.3	0.3	1	< 48 hours	0
Corneal opacity	0	0	0	0	0	0
Iridial inflammation	0	0.3	0.3		< 48 hours	0

<sup>\*</sup>Calculated on the basis of the scores at 24, 48, and 72 hours for EACH animal.

Remarks - Results

A single application of the test material to the non-irrigated eye of three rabbits produced iridial inflammation and moderate conjunctival irritation. One treated eye appeared normal at the 48 hour observation

with the remaining two eyes appearing normal at the 72 hour observation.

CONCLUSION The notified chemical is slightly irritating to the eye.

TEST FACILITY Safepharm Laboratories (2007f)

# B.5. Skin sensitisation – mouse local lymph node assay (LLNA)

TEST SUBSTANCE Notified chemical

METHOD OECD TG 429 Skin Sensitisation: Local Lymph Node Assay

EC Directive 2004/73/EC B.42 Skin Sensitisation (Local Lymph Node

Assay)

Species/Strain Mouse/CBA/Ca (CBA/CaBkl) Female

Vehicle Acetone/olive oil 4:1

Remarks - Method A preliminary screening test was conducted on 1 mouse using 25 µL of

undiluted test substance. No signs of systemic toxicity were noted. Mild

redness to the ears was noted post dose on Day 3.

 $\alpha$ -Hexylcinnamaldehyde was used as the positive control. The positive control assay was performed more than 6 months prior to the test substance assay. However, an assay using a different positive control in propylene glycol was conducted within 6 months of the test substance

assay.

#### RESULTS

Concentration	Proliferative response	Stimulation Index
(% w/w)	(Mean DPM/animal (SD))	(Test/Control Ratio)
Test Substance		
0 (vehicle control)	2329 (±2713)	
25	2170 (±696)	0.93
50	2244 (±366)	0.96
100	$3556 (\pm 1600)$	1.53
Positive Control		
5		2.50
10		4.03
25		9.13

Recalculation of the stimulation index using the median rather than the mean.

Concentration	Proliferative response	Stimulation Index
(% w/w)	(Median DPM/animal)	(Test/Control Ratio)
Test Substance		
0 (vehicle control)	1328	
25	2172	1.64
50	2302	1.73
100	3563	2.68

Remarks - Results

There were no deaths and no signs of systemic toxicity were noted in the test or control animals.

Body weight changes of the test animals were comparable to those seen in the control animals.

There was a large outlier present in the vehicle control, which had a disintegrations per minute (dpm) value of 7158. The other 4 animals in the vehicle control had dpm values of 853, 1328, 1454 and 851. The data was therefore recalculated using the medians rather than the means in order to minimise the effect of the single outlier.

A stimulation index of less than 3 was observed for all concentrations of the test material.

CONCLUSION There was no evidence of induction of a lymphocyte proliferative

response indicative of skin sensitisation to the notified chemical.

TEST FACILITY Safepharm Laboratories (2007g)

# **B.6.** Repeat dose toxicity

TEST SUBSTANCE Notified chemical

METHOD OECD TG 407 Repeated Dose 28-day Oral Toxicity Study in Rodents.

EC Directive 96/54/EC B.7 Repeated Dose (28 Days) Toxicity (Oral).

Species/Strain Sprague-Dawley Crl:CD® (SD) IGS BR strain rats

Route of Administration Oral – gavage

Exposure Information Total exposure days: 28 days

Vehicle Arachis oil BP

Remarks - Method Two recovery groups, each of five males and five females, were treated

with the high dose (750 mg/kg/day) or the vehicle alone for 28 consecutive days and then maintained without treatment for a further 14

days.

#### RESULTS

Group	Number and Sex	Dose	Mortality
	of Animals	mg/kg bw/day	
control	5 per sex	0	0
low dose	5 per sex	25	0
mid dose	5 per sex	150	0
high dose	5 per sex	750	0
control recovery	5 per sex	0	0
high dose recovery	5 per sex	750	0

Mortality and Time to Death

There were no unscheduled deaths during the study.

#### Clinical Observations

Incidental findings of increased salvation, generalised red/brown fur staining, fur loss and hunched posture were noted during the study. These isolated, incidental external changes were considered of no toxicological importance.

Behavioural Assessment – One female in the non-recovery high dose group showed hunched during weeks 3 and 4. In the absence of any supporting clinical observations to suggest an effect of neurotoxicity the finding is considered to be of no toxicological importance.

Functional Performance Tests - There were no toxicologically significant changes in the functional performance parameters measured.

Sensory Reactivity Assessments - There were no treatment-related changes in sensory reactivity.

Bodyweight – Significant increases in bodyweight were seen in male animals in the low dose group and female animals in the non-recovery high dose group. These increases in bodyweight are of no toxicological significance.

Food Consumption – There was no effect on food consumption or food efficiency throughout the course of the study in comparison to the controls.

*Water Consumption* - An increase in water consumption was detected for non-recovery males in the high dose group from day 15 onwards when compared to controls.

Laboratory Findings - Clinical Chemistry, Haematology, Urinalysis

Haematology – Non-recovery males treated in the high dose group showed an increase in clotting time, platelet count and activated partial thromboplastin time. Male animals in the high dose recovery group showed a decrease in the clotting time in comparison to the clotting time for the recovery control group. Male animals in the mid dose group showed a decreased total leucocyte count and differential leucocyte count (lymphocytes).

Blood Chemistry – Non-recovery animals of either sex in the high dose group showed an increase in plasma cholesterol levels. This effect was also seen in the mid dose males and high dose recovery females.

An increase in the albumin/globulin ratio was seen in all the male non-recovery dose groups and a decrease was seen in all the female non-recovery dose groups.

Non-recovery males in the mid and high dose groups showed a decrease in triglycerides and glucose levels and an increase in alanine aminotransferase. A decrease in creatine levels was also seen in non-recovery high dose males only.

In non-recovery high dose females an increase in the total protein was seen as well as decreases in the glucose and chloride levels. A decrease in glucose levels was also seen in mid dose females.

An increase in inorganic phosphorus was seen in the male high dose recovery group. In the female high dose recovery group a decrease in chloride levels and an increase in triglycerides levels was also seen.

#### Urinalysis

Females from all treatment groups showed an increase in reducing agents present in the urine. Males in the high dose groups had an increase in urine volume together with a reduction in the specific gravity. No effects were detected in the recovery animals following 14 days without treatment.

# Effects in Organs

Non-recovery animals of either sex in the mid and high dose groups showed an absolute and relative increase in liver weights. High dose females in the recovery group also showed an absolute and relative increase in liver weights.

In non-recovery male animals in the high dose group an increase in the weight of the epididymides, kidneys and testes was seen. In the high dose recovery groups the males showed a decrease in the weight of the adrenals and the female animals an increase in the weight of the liver and spleen.

There were no adverse findings noted at necroscopy.

Liver – Centrilobular hepatocyte enlargement was observed in the low, mid and high dose groups for both sexes, with greater severity seen in the high dose groups. There was also evidence of regression of the condition among the high dose recovery group.

*Thyroid* - Follicular cell hypertrophy was observed in relation to treatment for animals of either sex in the mid and high dose groups and male animals in the low dose group. There was evidence of regression of the condition among the high dose recovery group.

#### Remarks - Results

The treatment related effects were limited to microscopic liver and thyroid changes, with associated liver weight gains and a slightly altered metabolism. There were no associated inflammatory or degenerative changes in the organs affected, and so the effects are considered to be an adaptive response to the high doses of xenobiotics.

#### CONCLUSION

Oral administration of the test material to rats for a period of 28 consecutive days at dose levels of 750, 150 and 25 mg/kg/day resulted in treatment related effects at all dose levels and therefore a No Observed Effect Level (NOEL) could not be set.

The treatment related effects observed were primarily related to adaptive changes in the liver or were of no toxicological significance. Therefore, the No Observed (Adverse) Effect Level (NO(A)EL) was established as 750 mg/kg bw/day in this study.

TEST FACILITY

Safepharm Laboratories (2007h)

#### Genotoxicity - bacteria

Notified chemical TEST SUBSTANCE

**METHOD** OECD TG 471 Bacterial Reverse Mutation Test.

EC Directive 2000/32/EC B.13/14 Mutagenicity – Reverse Mutation Test

using Bacteria.

Plate incorporation procedure

S. typhimurium: TA1535, TA1537, TA98, TA100 Species/Strain

E. coli: WP2uvrA-

Metabolic Activation System Rat S9 fraction from phenobarbitone/β-napthoflavone induced rat liver

Concentration Range in

a) With metabolic activation:  $50 - 5000 \mu g/plate$ Main Test b) Without metabolic activation:  $50 - 5000 \mu g/plate$ Vehicle Dimethyl sulphoxide, test substance added as solution Remarks - Method No signs of toxicity were recorded in the preliminary test.

#### RESULTS

Metabolic	Test Substance Concentration (µg/plate) Resulting in:				
Activation	Cytotoxicity in	Cytotoxicity in	Precipitation	Genotoxic Effect	
	Preliminary Test	Main Test			
Absent					
Test 1	> 5000	> 5000	5000	negative	
Test 2		> 5000	5000	negative	
Present					
Test 1	> 5000	> 5000	5000	negative	
Test 2		> 5000	5000	negative	

Remarks - Results The test material was tested up to the maximum recommended dose level

> of 5000 µg/plate. No toxicologically significant increases in the frequency of revertant colonies were recorded for any of the bacterial strains, with any dose of the test material, either with or without

metabolic activation.

All the positive control chemicals used in the test induced marked increases in the frequency of revertant colonies thus confirming the

activity of the S9-mix and the sensitivity of the bacterial strains.

The notified chemical was not mutagenic to bacteria under the conditions CONCLUSION

of the test.

TEST FACILITY Safepharm Laboratories (2007i)

#### **B.8.** Genotoxicity - in vitro

TEST SUBSTANCE Notified chemical

**METHOD** OECD TG 473 In vitro Mammalian Chromosome Aberration Test.

EC Directive 2000/32/EC B.10 Mutagenicity - In vitro Mammalian

Chromosome Aberration Test.

Cell Type/Cell Line

Metabolic Activation System

Vehicle

Chinese Hamster Lung

Rat S9 fraction from phenobarbitone/β-napthoflavone induced rat liver

Dimethyl sulphoxide

Remarks - Method No significant protocol deviations. GLP compliant.

No adjustment for the purity of the notified chemical was made.

In test 1 the S9 mix was present at 5% of the final concentration, while in

test 2 it was present at 2% of the final concentration.

Metabolic Activation	Test Substance Concentration (μg/mL)	Exposure Period	Harvest Time
Absent			
Test 1	0*, 3.75, 7.5*, 15*, 22.5*, 30, 45	6 hours	24 hours
Test 2	0*, 1.88, 3.75, 7.5, 15*, 22.5*, 30*	24 hours	24 hours
Present			
Test 1	0*, 60.94, 121.88, 243.75, 487.5*, 975*, 1950*	6 hours	24 hours
Test 2	0*, 30, 60*, 120*, 240*, 360, 480	6 hours	24 hours

<sup>\*</sup>Cultures selected for metaphase analysis.

# RESULTS

Metabolic	Tes	g in:		
Activation	Cytotoxicity in Preliminary Test	Cytotoxicity in Main Test	Precipitation	Genotoxic Effect
Absent				
Test 1	30.47	> 22.5	> 22.5	negative
Test 2	32	22.5	> 30	negative
Present				
Test 1	1950	975	> 1950	negative
Test 2		240	120	negative

Remarks - Results The positive and vehicle controls gave satisfactory responses, confirming the validity of the test system.

The precipitate was seen to aggregate at 3900 µg/mL.

The test material did not induce any statistically significant increases in the frequency of cells with aberrations, or in the numbers of polyploid cells.

CONCLUSION The notified chemical was not clastogenic to Chinese Hamster Lung cells

treated in vitro under the conditions of the test.

TEST FACILITY Safepharm Laboratories (2007j)

# APPENDIX C: ENVIRONMENTAL FATE AND ECOTOXICOLOGICAL INVESTIGATIONS

#### **C.1.** Environmental Fate

#### C.1.1. Ready biodegradability

TEST SUBSTANCE Notified chemical

METHOD Japanese Guideline: Biodegradability Test of Chemical Substances by

Microorganisms

Inoculum Activated sludge (mixed liquor suspended solid 3450 mg/L).

Exposure Period 28 days Auxiliary Solvent None

Analytical Monitoring BOD, DOC, analysis of residual test substance.

Remarks - Method DOC measurements did not allow estimation of degradability as the test

substance was insoluble in water.

RESULTS There was no degradation of the test substance based on BOD.

Measurement of residual test material achieved 97% recovery.

Remarks - Results Primary degradation was confirmed by identification of the expected

transformation product.

CONCLUSION The notified chemical is not readily biodegradable.

TEST FACILITY Mitsubishi (2008).

#### C.1.2. Bioaccumulation

Bioaccumulation was not tested as the strong hydrophobicity and high partition coefficient of the notified chemical are considered to preclude significant bioaccumulation by minimising bioavailability.

# C.2. Ecotoxicological Investigations

# C.2.1. Acute toxicity to fish

TEST SUBSTANCE Notified chemical

METHOD OECD TG 203 Fish, Acute Toxicity Test – semi static.

Species Rainbow trout
Exposure Period 96 hours
Auxiliary Solvent None

Water Hardness 140 mg CaCO<sub>3</sub>/L

Analytical Monitoring HPLC (LOQ 0.000067 mg/L)

Remarks – Method Fish were exposed to the WAF obtained by mid-depth siphon from stirred

aqueous suspensions. The WAF remained clear and colourless throughout the exposure period. Analysis of test concentrations returned variable results, probably reflecting varying proportions of undissolved test material. Measured concentrations declined in the 24 hours between renewal of the test media, consistent with preliminary observations that the notified chemical was unstable in the light and dark at ambient

temperatures.

RESULTS All fish survived.

Concentration mg/L Number of Fish Mortality

Nominal	Actual		1 h	24 h	48 h	72 h	96 h
0	0	10	0	0	0	0	0
WAF	0.0011	10	0	0	0	0	0
WAF	0.0011	10	0	0	0	0	0

LC50 > 0.0011 mg/L at 96 hours (time weighted mean measured

concentration).

NOEC (or LOEC) 0.0011 mg/L at 96 hours.

CONCLUSION Nontoxic to fish to the limit of water solubility, as modulated by the

instability of the notified chemical.

TEST FACILITY SafePharm Laboratories (2008a).

# C.2.2. Acute toxicity to aquatic invertebrates

TEST SUBSTANCE Notified chemical.

METHOD OECD TG 202 Daphnia sp. Acute Immobilisation Test and Reproduction

Test - static.

Species Daphnia magna

Exposure Period 48 hours Auxiliary Solvent None

Water Hardness 250 mg CaCO<sub>3</sub>/L

Analytical Monitoring HPLC (LOQ 0.000067 mg/L)

Remarks – Method Daphnids were exposed to the WAF obtained by mid-depth siphon from

stirred aqueous suspensions. The WAF remained clear and colourless throughout the exposure period. Analysis of test concentrations returned variable results, probably reflecting varying proportions of undissolved test material. Measured concentrations declined over the test period, consistent with preliminary observations that the notified chemical was unstable in the light and dark at ambient temperatures, and with its

strongly hydrophobic nature.

RESULTS None of the twenty exposed daphnids were immobilised.

Concentra	tion mg/L	Number of D. magna	Number Immobilised		
Nominal	Actual		24 h	48 h	
0	0	20	0	0	
WAF	0.0082	20	0	0	

LC50 > 0.0082 mg/L at 48 hours (geometric mean measured concentration)

NOEC (or LOEC) 0.0082 mg/L at 48 hours

the normal range.

CONCLUSION Nontoxic to daphnids to the limit of water solubility, as modulated by the

instability of the notified chemical.

TEST FACILITY SafePharm Laboratories (2008b)

#### C.2.3. Algal growth inhibition test

TEST SUBSTANCE Notified chemical.

METHOD OECD TG 201 Alga, Growth Inhibition Test.

Species Desmodesmus subspicatus

Exposure Period 72 hours

Concentration Range Nominal: 6.25-100 mg/L

Actual: 0.000087-0.00018 mg/L (geometric mean measured

concentrations)

Auxiliary Solvent

None

Analytical Monitoring

HPLC (LOQ 0.00011 mg/L)

Remarks - Method Algae were exposed to the WAF obtained by mid-depth siphon from

stirred aqueous suspensions followed by centrifugation. The WAF was clear and colourless. Measured concentrations declined below the LOQ over the test period, consistent with preliminary observations that the

notified chemical was unstable in the culture medium.

RESULTS The algal response at the highest test concentration (0.00018 mg/L) was

significantly different from that at lower concentrations. Growth was inhibited by 13%, and biomass by 19%. The NOECs for growth and

biomass were 0.00014 mg/L.

Remarks - Results Cell concentrations in controls increased by a factor of 46, satisfying the

validity criterion of a 16 fold increase. Results with the reference

substance potassium dichromate were within the normal range.

CONCLUSION Nontoxic to green algae to the limit of water solubility, as modulated by

the instability of the notified chemical.

TEST FACILITY SafePharm Laboratories (2008c)

# C.2.4. Inhibition of microbial activity

TEST SUBSTANCE Notified chemical

METHOD OECD TG 209 Activated Sludge, Respiration Inhibition Test.

Inoculum Activated sludge from UK sewage treatment plant handling

predominantly domestic sewage.

Exposure Period 3 hours

Concentration Range Nominal: 1000 mg/L

Actual: not measured.

Remarks – Method Oily globules of the test substance were observed on the surface and

throughout the test medium.

RESULTS

 $\begin{array}{ll} IC50 & > 1000 \text{ mg/L} \\ NOEC & 1000 \text{ mg/L} \end{array}$ 

Remarks – Results Oxygen consumption at 3 hours varied by only 1% between test flasks

and controls. Results with the reference substance potassium dichromate

were within the normal range.

CONCLUSION The notified chemical does not inhibit the respiration of activated sludge.

TEST FACILITY SafePharm Laboratories (2007k)

# **BIBLIOGRAPHY**

- EASE (1997) EASE (Estimation and Assessment of Substance Exposure) for Windows version 2.0; Health and Safety Executive, UK and AIAI, Edinburgh.
- FORS (Federal Office of Road Safety) (1998) Australian Code for the Transport of Dangerous Goods by Road and Rail (ADG code), 6th Edition, Canberra, Australian Government Publishing Service
- NOHSC (1994) National Code of Practice for the Labelling of Workplace Substances [NOHSC:2012(1994)]. National Occupational Health and Safety Commission, Canberra, Australian Government Publishing Service.
- NOHSC (2001) National Standard for the Storage and Handling of Workplace Dangerous Goods [NOHSC:1015(2001)]. National Occupational Health and Safety Commission, Canberra, Australian Government Publishing Service.
- NOHSC (2003) National Code of Practice for the Preparation of Material Safety Data Sheets, 2<sup>nd</sup> edition [NOHSC:2011(2003)]. National Occupational Health and Safety Commission, Canberra, Australian Government Publishing Service.
- NOHSC (2004) Approved Criteria for Classifying Hazardous Substances, 3<sup>rd</sup> edition [NOHSC:1008(2004)]. National Occupational Health and Safety Commission, Canberra, AusInfo.
- RIVM (2006) General Fact Sheet. Prepared for the National Institute of Public Health and the Environment (RIVM) by Bremmer HJ, de Lodder P'hLCH & van Engelen JGM (RIVM report 320104002/2006). Bilthoven, The Netherlands.
- SafePharm Laboratories (2007a) OS219479: Determination of general physico-chemical properties (SPL Project Number: 0525/0750, 17 April 2007) Safepharm Laboratories Ltd, Derbyshire, UK. (Unpublished report provided by Lubrizol International Inc).
- SafePharm Laboratories (2007b) OS219479: Determination of hazardous physico-chemical properties (SPL Project Number: 0525/0751, 22 March 2007). Safepharm Laboratories Ltd, Derbyshire, UK. (Unpublished report provided by Lubrizol International Inc).
- SafePharm Laboratories (2007c) OS219479: Acute Oral Toxicity in the Rat Fixed Dose Method (SPL Project Number: 0525/0752, 26 March 2007). Safepharm Laboratories Ltd, Derbyshire, UK. (Unpublished report provided by Lubrizol International Inc).
- SafePharm Laboratories (2007d) OS219479: Acute Dermal Toxicity (Limit Test) in the Rat (SPL Project Number: 0525/0753, 11 April 2007). Safepharm Laboratories Ltd, Derbyshire, UK. (Unpublished report provided by Lubrizol International Inc).
- SafePharm Laboratories (2007e) OS219479: Acute Dermal Irritation in the Rabbit (SPL Project Number: 0525/0754, 14 March 2007). Safepharm Laboratories Ltd, Derbyshire, UK. (Unpublished report provided by Lubrizol International Inc).
- SafePharm Laboratories (2007f) OS219479: Acute Eye Irritation in the Rabbit (SPL Project Number: 0525/0755, 14 March 2007). Safepharm Laboratories Ltd, Derbyshire, UK. (Unpublished report provided by Lubrizol International Inc).
- SafePharm Laboratories (2007g) OS219479: Local Lymph Node Assay in the Mouse (SPL Project Number: 0525/0756, 11 April 2007). Safepharm Laboratories Ltd, Derbyshire, UK. (Unpublished report provided by Lubrizol International Inc).
- SafePharm Laboratories (2007h) OS219479: Twenty-Eight Day Repeated Dose Oral (Gavage) Toxicity Study in the Rat (SPL Project Number: 0525/0757, 31 July 2007). Safepharm Laboratories Ltd, Derbyshire, UK. (Unpublished report provided by Lubrizol International Inc).
- SafePharm Laboratories (2007i) OS219479: Reverse Mutation Assay "Ames Test" using *Salmonella typhimurium* and *Escherichia coli* (SPL Project Number: 0525/0759, 16 February 2007). Safepharm Laboratories Ltd, Derbyshire, UK. (Unpublished report provided by Lubrizol International Inc).
- SafePharm Laboratories (2007j) OS219479: Chromosome aberration test in CHL cells *in vitro* (SPL Project Number: 0525/0758, 30 March 2007). Safepharm Laboratories Ltd, Derbyshire, UK. (Unpublished report provided by Lubrizol International Inc).

SafePharm Laboratories (2007k) OS219479: Assessment of the inhibitory effect on the respiration of activated sewage sludge (SPL Project Number: 0525/0763, 13 June 2007) Safepharm Laboratories Ltd, Derbyshire, UK. (Unpublished report provided by Lubrizol International Inc).

- SafePharm Laboratories (2008a) OS219479: Acute toxicity to rainbow trout (*Oncorhynchus mykiss*) (SPL Project Number: 0525/0760, 27 February 2008) Safepharm Laboratories Ltd, Derbyshire, UK. (Unpublished report provided by Lubrizol International Inc).
- SafePharm Laboratories (2008b) OS219479: Acute toxicity to *Daphnia magna* (SPL Project Number: 0525/0761, 19 February 2008) Safepharm Laboratories Ltd, Derbyshire, UK. (Unpublished report provided by Lubrizol International Inc).
- SafePharm Laboratories (2008c) OS219479: Algal growth inhibition test (SPL Project Number: 0525/0762, 29 February 2008) Safepharm Laboratories Ltd, Derbyshire, UK. (Unpublished report provided by Lubrizol International Inc).
- United Nations (2003) Globally Harmonised System of Classification and Labelling of Chemicals (GHS). United Nations Economic Commission for Europe (UN/ECE), New York and Geneva.